Over the years, there has been a high demand for developing new safe and effective drug
carriers for cancer therapy. Emerging studies have indicated that exosomes can serve as …

Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of
molecular mechanisms including MET gene amplification, mutation, rearrangement, and …

Inhibitors of the receptor tyrosine kinase c-MET are currently used in the clinic to target
oncogenic signaling in tumor cells. We found that concomitant c-MET inhibition promoted …

The role of aberrant hepatocyte growth factor receptor (c-MET, also known as tyrosine-
protein kinase MET)/hepatocyte growth factor (HGF) signaling in cancer progression and …

Abstract Heat shock protein 90 (HSP90), a highly and unique chaperone, presents as a
double-edged sword. It plays an essential role in many physiological and pathological …

ABSTRACT MP0250 is a multi-domain drug candidate currently being tested in clinical trials
for the treatment of cancer. It comprises one anti-vascular endothelial growth factor-A (VEGF …

Abstract c-MET is a membrane spanning receptor tyrosine kinase for hepatocyte growth
factor (HGF) also termed scatter factor. Transmitting signals from mesenchymal to epithelial …

Inflammation resolution is an active process that involves cellular events such as apoptosis
and efferocytosis, which are key steps in the restoration of tissue homeostasis. Hepatocyte …

Neutrophils are the first line of defence against invading pathogens. Although neutrophils
are well-known professional killers, some pathogens including Leishmania (L.) parasites …

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic
management has advanced to identify various critical oncogenic mutations that promote …